Clinical Insights: February 8, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Jesduvroq™ (daprodustat) – New Drug Approval – February 1, 2023 – The U.S. Food and Drug Administration approved Jesduvroq™ tablets (daprodustat) as the first oral treatment for anemia (decreased…
Clinical Insights: February 1, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Jaypirca™ (pirtobrutinib) Tablets – New Drug Approval – January 27, 2023 – The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca™, Eli Lilly and Company) for…
Clinical Insights: January 25, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Brenzavvy™ (bexagliflozin) Tablets – New Drug Approval – January 20, 2023 – TheracosBio announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy™ (bexagliflozin), an oral sodium-glucose…
Clinical Insights: January 18, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Rykindo® (risperidone) for Extended-Release Injectable Suspension – New Drug Approval – January 13, 2023 – Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing…
Clinical Insights: January 11, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Leqembi™ (lecanemab-irmb) Injection New Drug Approval – January 6, 2023 – The U.S. Food and Drug Administration approved Leqembi™ (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of…
Clinical Insights: December 28, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Sunlenca® (lenacapavir) – New Drug Approval – December 22, 2022 – Gilead Sciences, Inc. announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by…
Clinical Insights: December 21, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Adstiladrin® (nadofaragene firadenovec-vncg) – New Drug Approval – December 16, 2022 – The U.S. Food and Drug Administration approved Adstiladrin® (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells)…
Clinical Insights: June 2, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Vtama® (tapinarof) Cream – New Drug Approval – May 24, 2022 – Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced that the…
Clinical Insights: May 25, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Vidaza® (azacytidine) Injection – New Drug Approval – May 20, 2022 – The Food and Drug Administration approved azacitidine (Vidaza®, Celgene Corp.) for pediatric patients with newly diagnosed juvenile…
Clinical Insights: May 18, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Mounjaro™ (tirzepatide) Injection – New Drug Approval – May 13, 2022 – The U.S. Food and Drug Administration approved Mounjaro™ (tirzepatide) injection to improve blood sugar control in adults…
Clinical Insights: May 11, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Voquezna™ Dual Pak™ (amoxicillin and vonoprazan) Voquezna™ Triple Pak™ (vonoprazan, amoxicillin, clarithromycin) Co-Packaged – New Drug Approval – May 3, 2022 – Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused…
Clinical Insights: May 4, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Cuvrior™ (trientine tetrahydrochloride) Tablets – New Drug Approval – May 2, 2022 – Orphalan SA, an international orphan drug development and commercialisation company, announces approval of Cuvrior™, a new…